Quantcast
Channel: drug development – IPWatchdog.com | Patents & Intellectual Property Law
Browsing all 63 articles
Browse latest View live

Hunting Bayh-Dole Vampires

The government is funding basic research at universities, not drug development. Bayh-Dole allows schools to own resulting inventions and license them for commercialization. These discoveries are more...

View Article



Patents, Drugs and the Moral High Ground

There are millions and millions of people dying each year from all kinds of illnesses that are easily preventable using simple technologies and drugs that are off patent. None of the zealots or patent...

View Article

Patents are Just the Start

Capitol Hill is frequently the setting for both grandstanding and pandering, and given the prevailing political and public sentiment it is also frequently a place where businesses find an inhospitable...

View Article

The High Cost of Making Pharmaceuticals

It is nearly universally accepted (and for a reason) that the process from discovery to market is long and costly. Drugs to not invent themselves and there are significant costs associated with nearly...

View Article

When Lives Depend on Tech Transfer

Nothing clarified the stakes in orphan drug development like hearing Ron Bartek describe how after 16 years a promising treatment for his son’s disease finally emerged with TRND’s help. The therapy...

View Article


Around and Around We Go: The Drug Development Debate

Every once and a while we get a clear example of the gulf between those battling over important public policy issues and can understand why the public and policy makers are confused by resulting...

View Article

Why is the Cystic Fibrosis Foundation under attack for funding the drug of...

Cystic fibrosis creates a thick, sticky mucus that builds up in the airways, causing infections, and making it difficult to breathe. Chronic pain is a common problem for patients, which increases...

View Article

Bayh-Dole Forecast: Sunny with 20% chance of Shark Attack

How tragic if the United States of America turns its patent system into a tool that rich and powerful companies use to suppress innovation that challenges their comfortable status quo. But Just because...

View Article


Bristol-Myers, AstraZeneca and AmGen maintain strong new drug pipelines

There’s been a lot of positive activity in recent months for Bristol-Myers Squibb of New York City. In early March, the U.S. Food and Drug Administration approved the use of BMS’s immunotherapy drug...

View Article


The looming patent nightmare facing the pharmaceutical industry

During the last hearing of the House Judiciary Committee there was an attempt to insert language via amendment that would make it impossible for Kyle Bass and others to challenge pharmaceutical patents...

View Article

What ‘The Economist’ Doesn’t Get About Patents

In what can only be characterized as a bizarre, rambling, and intellectually dishonest article, 'The Economist' has inexplicably taken the position that patents are not necessary for innovation. The...

View Article

The Need for Regulatory Data Protection in the TPP: Why Australia’s Got it...

While patents protect innovations that are novel, nonobvious and useful, data exclusivity protects the extensive preclinical and clinical trial data required to establish new therapies as safe and...

View Article

Will More Regulation Create Cheaper Drugs?

The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full boil. Two recent actions turned up the heat to full...

View Article


IP Protection Critical for BioPharma Given Number, Cost and Complexity of...

Biopharmaceutical innovation is difficult, expensive, time-consuming, and risky. More so now than ever. A 2014 study by Tufts University’s Center for the Study of Drug Development calculated that a...

View Article

UN Access to Medicine Recommendations Will Increase Human Suffering

The pending report of the UN Secretary General's High Level Panel on Access to Medicines not only attacks the patent system as predicted, but proposes giving the organization oversight of drug...

View Article


Public Health and Bioscientific War on Superbugs is Hobbled by IP Uncertainties

How will our patent system treat this wonderful new discovery? How long will it take before its curative benefits can be deployed ? We can only hope that DC’s meddlers in our innovation ecosystem read...

View Article

Property Rights Key to Bayh-Dole Act’s Success

The focus of the political advocates pushing march-in may be lower drug costs. But the long-term costs of ripping apart IP rights are far higher and more fundamental than advocates acknowledge. The...

View Article


Winning the Drug Development Debate

We create two new companies around academic inventions every day of the year. The critical role such companies play in drug development is clear. The successful integration of public research...

View Article

Advice for the Trump Administration and New Congress: Protect Bayh-Dole and...

Bayh-Dole is running on autopilot without Executive branch oversight and U.S. patents are no longer the world's gold standard. Without a course correction, we could be headed back to the bad old...

View Article

Passage of the 21st Century Cures Act and its Potential Implications on...

With the Cures Act now signed into law, the incoming Trump administration has an opportunity to advance the broad-spectrum medical countermeasure goal set forth by the U.S. Department of Health and...

View Article
Browsing all 63 articles
Browse latest View live




Latest Images